DCC-3116

Cat. No.:	HY-160699
CAS No.:	2543673-19-2
Molecular Formula:	$C_{26}H_{36}F_3N_7O_2$
Molecular Weight:	535.6
Target:	ULK; Ras
Pathway:	Autophagy; GPCR/G Protein; MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	DCC-3116 is an orally active ULK1/2 inhibitor. DCC-3116 can promote autophagy in lung cancer cells by inhibiting $KRAS^{G12C}$ signaling, thereby inhibiting the proliferation of lung cancer cells and exerting anti-cancer effects[1].		
IC_{50} & Target	ULK1	ULK2	KRas G12C
In Vitro	DCC-3116 (100 nM, 72 h) alone inhibits the proliferation of NCI-H2122 and Calu-1 cells, decreases the expression of pS318-ATG13, and has a synergistic effect when combined with Sotorasib (HY-114277)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

In Vivo

DCC-3116 (3 or 30 mg/kg/day for 56 days, p.o. and p.i.) alone or in combination with Sotorasib (HY-114277) can inhibit tumor growth in mouse models of NSCLC lung cancer[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	mouse models of NSCLC lung cancer (adult mice were initiated between 6-8 weeks of age) [1]
Dosage:	3 or 30 mg/kg/day for 56 days
Administration:	p.o. and p.i
Result:	Inhibited mice tumor growth and improved mice survival rate, while significantly reducing mice body weight (>20%).

REFERENCES

[1]. Ghazi PC, et al. Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer. bioRxiv [Preprint]. 2024 Feb 8:2024.02.06.579200.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA